Skip to main navigation Skip to search Skip to main content

Broadening the tumor antigens panorama for cancer vaccines - All the way to the dark matter of the genome

  • Anna Maria Di Giacomo
  • , Andrea Anichini
  • , Teresa Maria Rosaria Noviello
  • , Katherine B Chiappinelli
  • , Michael Weller
  • , Ramy Ibrahim
  • , Michael Lahn
  • , Michael Smith
  • , Alexander M M Eggermont
  • , Bernard A Fox
  • , Michele Maio*
  • *Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Downloads (Pure)

Abstract

In recent decades the field of Tumor Antigens (TAs) has expanded and led to the discovery of non-canonical ("dark genome") TAs. Such TAs may provide new opportunities for the development of cancer vaccines capable of inducing robust and durable antitumor immune responses. In addition to these improved vaccine concepts, the combination of novel vaccines with immune checkpoint inhibitors (ICI) may also improve immune responses and thus result in clinical benefit. While ICIs have shown to be useful combination agents for future vaccine development, the role of epigenetic modulators has not been fully appreciated. Recent discoveries suggest that epigenetic agents can reactivate non-canonical antigens. Thus, epigenetic modulators should be considered in future vaccine trials either in combination with ICIs or with vaccines.

Original languageEnglish
Article number117796
Number of pages8
JournalEuropean Journal of Cancer
Volume249
Early online date24 Oct 2026
DOIs
Publication statusE-pub ahead of print - 24 Oct 2026

Fingerprint

Dive into the research topics of 'Broadening the tumor antigens panorama for cancer vaccines - All the way to the dark matter of the genome'. Together they form a unique fingerprint.

Cite this